Logo Volv Global
Contact

WHIM Syndrome

WHIM syndrome is an ultra-rare inherited immune disorder causing neutropenia, warts and recurrent infections, split across four specialties so it is difficult to diagnose and often missed for years.
GET IN TOUCH
LEARN MORE
About WHIM Syndrome

In numbers

  • An estimated 100 to 200 patients are diagnosed with WHIM syndrome worldwide, spanning around 60 to 66 reported families.
  • EU4 and UK data suggest around 48 diagnosed prevalent cases, with roughly 5 to 8 in England and 3 to 6 in Germany.
  • Diagnostic delay of around 10 years means a meaningful share of the eligible population in England and Germany likely remains undiagnosed.

Special details

  • WHIM syndrome affects males and females equally, consistent with its autosomal dominant, non-sex-linked inheritance.
  • Cases without a family history are typically diagnosed later, around age 5, compared with a median of 1.3 years in familial cases.
  • European ancestry predominates, with France and Italy reporting the highest rates among Western European countries.
Signs and symptoms of WHIM Syndrome
Patients wait around 10 years from symptom onset to molecular diagnosis when there is no family history, as the four-part phenotype spans dermatology, immunology, infectious disease and haematology.
Talk to our team
Recurrent infections

Recurrent infections

Sinusitis, otitis media and pneumonia from early childhood, driven by neutropenia and low antibody levels.

Persistent neutropenia

Persistent neutropenia

Low neutrophil counts from infancy, often the first laboratory clue before diagnosis.

Refractory HPV warts

Refractory HPV warts

Extensive cutaneous and mucosal warts that resist standard treatment and can become disfiguring.

Myelokathexis

Myelokathexis

A distinctive bone marrow finding of mature neutrophils trapped in the marrow, confirmed only by biopsy.

Low immunoglobulins

Low immunoglobulins

Reduced IgG, IgA and IgM with impaired vaccine responses, raising long-term infection risk.

Key challenges from product development to launch

Strategy and Business

Strategy and Business

  • The wrong disease or indication selected for investment
  • Indications tackled in the wrong order due to shaky success estimates
  • R&D returns slipping below the cost of capital
Clinical Development

Clinical Development

  • Trials delayed by low patient recruitment
  • High screen-failure rates that raise trial cost
  • Mixed cohorts that make the signals difficult to detect
HEOR, Access & Value

HEOR, Access & Value

  • A value case that arrives too late or is underdeveloped
  • Eligible population under-counted, budget-impact case unsubstantiated
  • Approved by the regulator, delayed at HTA
Medical Affairs

Medical Affairs

  • Fragmented, differently-coded healthcare data
  • Diagnostic delay that is long and unequal
  • No shared evidence base across functions
Launch and Commercial

Launch and Commercial

  • Launch planned without a view of the number of findable patients
  • Targeting too broad a population slows early uptake
  • RWE started too late to build the case

How Volv Global Helps

The earliest pipeline decisions carry lasting consequences: the wrong indication chosen, indications pursued in the wrong order, or capital committed where expected returns already trail its cost. Mistakes made this early are expensive to correct later.

inTrigue

Finds the true reachable population per candidate, so indication choices rest on evidence.

volv.global/finding-patients

inFlow

Adds probability-of-success and outcome evidence to help prioritise the pipeline.

volv.global/predict-patient-outcomes

When patients cannot be found, recruitment stalls and the burn rate climbs. High screen-failure rates add further cost and delay, and a mixed cohort makes the results harder to interpret.

inTrigue

Finds the undiagnosed and mis-coded patients conventional feasibility misses, widening the recruitable pool.

volv.global/finding-patients

inCare

Surfaces diagnosed-but-hidden, trial-eligible patients already in the data, so sites enrol faster.

volv.global/stratifying-patient-cohorts

inFlow

Predicts who will progress or respond, enriching the cohort so the signal is not diluted.

volv.global/predict-patient-outcomes

Without strong, timely evidence, payers can restrict access or cut the price. An under-characterised population weakens the budget case, and HTA approval demands more evidence than regulatory approval alone.

inFlow

Generates the real-world evidence and outcomes payers ask for, ahead of the submission deadline.

volv.global/predict-patient-outcomes

inTrigue

Finds the undiagnosed patients missing from the count, so the eligible population holds up under scrutiny.

volv.global/finding-patients

inCare

Surfaces the diagnosed-but-eligible patients who expand the eligible population count.

volv.global/stratifying-patient-cohorts

Healthcare data is fragmented across markets, so evidence has to be rebuilt market by market, slowing decisions. Time to an accurate diagnosis varies by who the patient is and where they are treated.

inTrigue

Works across fragmented, differently-coded data by design, so insight holds up country to country without a rebuild.

volv.global/finding-patients

inAdvance

Detects patients ahead of typical diagnosis, closing the gap in awareness and pathway that drives unequal delay.

volv.global/earlier-detection

A launch planned without a view of findable patients is poorly resourced from day one. Targeting too broad a population slows early uptake, and real-world evidence gathered too late leaves little time to build a strong access dossier.

inTrigue

Finds the treatable patients, so the launch is planned against real demand.

volv.global/finding-patients

inCare

Adds the eligible, reachable patients that launch planning is missing.

volv.global/stratifying-patient-cohorts

inFlow

Builds the access evidence early enough to matter.

volv.global/predict-patient-outcomes

Case Studies about Immunology diseases

Insights

Logo Volv Global

Your challenge

Our technology

Our solutions

Knowledge Hub

Meet Volv Global

Proprietary Machine Learning Methodology